Mode
Text Size
Log in / Sign up

Specific natural products modulate the NRF2-ferroptosis axis in preclinical models of hepatocellular carcinomaNatural products may help treat liver cancer and injury

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that specific natural products show promise for selective NRF2 modulation in preclinical liver models.

This mini-review explores the impact of various natural products on the NRF2-ferroptosis axis in preclinical models of hepatocellular carcinoma (HCC) and non-malignant liver injury. The review synthesizes findings on how specific compounds, including Polyphyllin I, tiliroside, ponicidin, picropodophyllin, curcumin, esculetin, sappanone A, and decursin, restore ferroptotic sensitivity in HCC models by suppressing the p62-KEAP1-NRF2 pathway or its SLC7A11/GPX4 effectors.

Additionally, the review identifies ginsenoside Rg1, thymoquinone, and hinokitiol as agents that activate NRF2 in models of non-malignant liver injury, providing hepatoprotection. The authors suggest these findings support the potential for tumor-selective NRF2 modulation rather than indiscriminate systemic inhibition.

Significant limitations are noted, including a lack of pharmacokinetic, target-engagement, and toxicologic evidence. Furthermore, clinical evidence is currently limited. These factors suggest that while these natural products show promise in preclinical models, their clinical utility remains uncertain and requires further investigation to establish safety and efficacy in human patients.

How this fits prior evidence

This review addresses a gap in the understanding of NRF2 modulation in liver disease. While previous coverage noted that surgical resection plus postoperative TACE yields recurrence-free status in rare primary clear cell liver carcinoma, this review focuses on the biochemical modulation of the NRF2-ferroptosis axis using natural products in preclinical models. It does not directly relate to the efficacy of bevacizumab, serplulimab, or ICI-based therapies mentioned in prior coverage.

Living with liver disease or cancer is incredibly hard on the body. New research is looking into how natural compounds might help protect the liver and make cancer cells easier to fight. Specifically, scientists looked at how these substances interact with a pathway in the body that helps manage cell death.

In early laboratory models, several natural products like curcumin and decursin helped restore the ability of liver cancer cells to die when treated. Other compounds, such as ginsenoside Rg1 and hinokitiol, showed promise in protecting liver tissue from non-cancerous injuries. These findings suggest that some natural substances might target cancer specifically rather than affecting the whole body at once.

It is important to remember that this research was done in laboratory models, not in people. Because of this, we still have very little information on how these substances move through the human body, how they interact with specific targets in humans, or what their safety profile looks like. More clinical studies are needed to see if these results can actually help patients.

What this means for you:
Specific natural compounds show potential to protect liver tissue and sensitize liver cancer cells in lab models.

Common questions

Which natural products showed promise for liver health?

Several natural products showed potential in laboratory models. Ginsenoside Rg1, thymoquinone, and hinokitiol were found to activate a protective pathway in models of non-malignant liver injury. Other compounds like curcumin, decursin, and tiliroside helped cancer cells become more sensitive to treatment. You should talk to your doctor about any supplements.

Is this treatment safe for humans yet?

Not yet. This research was conducted using preclinical models, which means it was tested in a lab setting rather than in people. There is currently limited evidence regarding the safety, toxicology, or how these substances move through the human body. You must consult a medical professional before trying any new treatments.

How is this different from current treatments?

Current treatments often involve medications like sorafenib or bevacizumab. The research into natural products focuses on a specific pathway to target cancer cells more selectively. However, because the evidence is still in the early stages, these natural compounds are not yet a replacement for standard medical care.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Hepatocellular carcinoma (HCC) remains a major cause of cancer mortality. First-line systemic therapy is now led by immune checkpoint inhibitor (ICI)-based regimens, notably atezolizumab plus bevacizumab and durvalumab plus tremelimumab, whereas sorafenib and lenvatinib are used mainly when immunotherapy is unsuitable and in later lines; resistance limits the durability of both strategies. Ferroptosis, an iron-dependent form of regulated cell death driven by phospholipid peroxidation, offers a potential strategy for overcoming this resistance. Nuclear factor erythroid 2-related factor 2 (NRF2) is a central but context-dependent regulator of this vulnerability. Transient NRF2 activation protects non-transformed hepatocytes from oxidative injury, whereas constitutive activation in HCC reinforces SLC7A11-and GPX4-dependent antioxidant defenses, promotes immune escape, and supports drug resistance. This mini-review evaluates how natural products and related formulations modulate this dual program. Polyphyllin I, tiliroside, ponicidin, picropodophyllin, curcumin, esculetin, sappanone A, and decursin act at distinct upstream nodes but converge on suppression of the p62-KEAP1-NRF2 pathway or its SLC7A11/GPX4 effectors, thereby restoring ferroptotic sensitivity in preclinical HCC models. In contrast, ginsenoside Rg1, thymoquinone, and hinokitiol activate NRF2 in models of non-malignant liver injury. Because the FSP1-CoQ10 and DHODH systems defend membranes against phospholipid peroxidation independently of GPX4, residual activity in these parallel arms can limit the efficacy of agents directed at the NRF2-SLC7A11-GPX4 axis. These findings support tumor-selective NRF2 modulation rather than indiscriminate systemic inhibition. Biased disruption of the KEAP1-p62 interaction and tumor-targeted nucleic-acid delivery provide proof of concept, but translation is constrained by limited pharmacokinetic, target-engagement, toxicologic, and clinical evidence.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.